We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

142 hedge funds and large institutions have $195M invested in Zentalis Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 57 increasing their positions, 31 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 31

38% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 24

4% more funds holding

Funds holding: 136 → 142 (+6)

3% more call options, than puts

Call options by funds: $229K | Put options by funds: $222K

9.41% less ownership

Funds ownership: 99.8% → 90.39% (-9.4%)

25% less capital invested

Capital invested by funds: $261M → $195M (-$66M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
142
Holders Change
+6
Holders Change %
+4.41%
% of All Funds
1.87%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
33
Increased
57
Reduced
31
Closed
24
Calls
$229K
Puts
$222K
Net Calls
+$7K
Net Calls Change
+$86K

Top Buyers

1
IHAM
Integral Health Asset Management
New York
+$3.44M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.63M
3
OM
Opaleye Management
Massachusetts
+$2.62M
4
AC
Almitas Capital
California
+$2.18M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.64M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$16M
2
EAM
Eventide Asset Management
Massachusetts
-$13.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$4.4M
4
DC
Decheng Capital
California
-$2.52M
5
Bank of America
Bank of America
North Carolina
-$1.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$42.3M – – –
EAM
2
Eventide Asset Management
Massachusetts
$13.6M -$13.3M -4,072,842 -48%
BlackRock
3
BlackRock
New York
$12.8M -$1.71M -523,084 -11%
Vanguard Group
4
Vanguard Group
Pennsylvania
$9.91M -$4.4M -1,341,467 -29%
Citadel Advisors
5
Citadel Advisors
Florida
$9.75M +$1.64M +499,206 +18%
DC
6
Decheng Capital
California
$7.08M -$2.52M -770,000 -25%
OM
7
Opaleye Management
Massachusetts
$5.36M +$2.62M +800,500 +83%
Morgan Stanley
8
Morgan Stanley
New York
$5.19M +$333K +101,621 +6%
AC
9
Almitas Capital
California
$4.93M +$2.18M +665,968 +69%
Primecap Management
10
Primecap Management
California
$4.61M +$74.1K +22,600 +2%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$3.98M +$68.4K +20,864 +2%
State Street
12
State Street
Massachusetts
$3.91M +$139K +42,372 +3%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$3.76M +$363K +110,882 +10%
Verition Fund Management
14
Verition Fund Management
Connecticut
$3.69M -$941K -287,226 -19%
MB
15
MPM BioImpact
Massachusetts
$3.35M -$1.18M -358,950 -24%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$3.23M +$2.63M +804,017 +305%
IHAM
17
Integral Health Asset Management
New York
$3.18M +$3.44M +1,050,000 New
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$2.97M -$187K -57,056 -6%
TCM
19
Tybourne Capital Management
Hong Kong
$2.91M – – –
Millennium Management
20
Millennium Management
New York
$2.9M +$234K +71,477 +8%
P
21
Pfizer
New York
$2.89M +$3.13M +953,834 New
Goldman Sachs
22
Goldman Sachs
New York
$2.78M +$931K +284,043 +45%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$2.7M -$851K -259,700 -23%
JP Morgan Chase
24
JP Morgan Chase
New York
$2.6M +$1.21M +370,511 +76%
N
25
Nuveen
North Carolina
$1.94M +$547K +167,062 +35%
1
2 3 4 5

ZNTL Hedge Fund Activity: Q4 2024 in Review

142 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2024, worth a combined $195M — down 25% from $261M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ZNTL positions and 24 closed out — a net gain of 9 holders — while 57 added to existing stakes and 31 trimmed.

The largest buyer was Integral Health Asset Management, opening a new position worth an estimated $3.44M. The largest seller was Fidelity Investments, cutting an estimated $16M.

  • 142 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2024, up from 136 in Q3 2024.
  • Funds reported $195M of Zentalis Pharmaceuticals stock for Q4 2024, down 25% quarter-over-quarter.
  • 33 funds opened new Zentalis Pharmaceuticals positions in Q4 2024 and 24 closed out, a net change of +9 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2024 was Integral Health Asset Management, an estimated $3.44M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2024 was Fidelity Investments, an estimated $16M sold.

Based on aggregated 13F filings for Q4 2024.